Important points to consider when evaluating the response to drug therapy for lung cancer

Medicine and Dentistry

• Progressive Disease 100%
• Evaluation Study 66%
• Computed Tomography 66%
• Response Evaluation Criteria in Solid Tumors 66%
• Neoplasm 33%
• Drug 33%
• Chemotherapeutic Agent 33%
• Lung Cancer 33%
• Diffusion MRI 33%
• Positron Emission Tomography-Computed Tomography 33%
• Fluorodeoxyglucose 33%
• Therapy Effect 33%
• Drug Therapy 33%
• Perfusion 33%
• Immunotherapy 33%
• Functional Imaging 33%
• Personalized Medicine 33%
• Drug Therapy for Lung Cancer 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Immune Checkpoint Inhibitor 66%
• Drug 33%
• Neoplasm 33%
• Prognosis 33%
• Lung Cancer 33%
• Immunotherapy 33%
• Fluorodeoxyglucose 33%

Biochemistry, Genetics and Molecular Biology

• Dual Energy Computed Tomography 33%